MedTrace Logo

BIOSTEMI Extended Survival

NCT05484310 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1300

Last updated 2023-11-29

No results posted yet for this study

Summary

The objective of the BIOSTEMI ES study is to assess the long-term clinical outcomes with the Orsiro ultrathin-strut biodegradable polymer sirolimus-eluting stent compared to the Xience thin-strut durable polymer everolimus-eluting stent up to 5 years of follow-up among patients with STEMI undergoing primary PCI, enrolled in the BIOSTEMI trial.

Conditions

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    collaborator OTHER

  • University Hospital, Geneva

    lead OTHER

Principal Investigators

  • Thomas Pilgrim, Pr · Insel Gruppe AG, University Hospital Bern

  • Juan F. Iglesias, PD Dr · University Hospital, Geneva

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-15
Primary Completion
2023-04-30
Completion
2023-10-28

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05484310 on ClinicalTrials.gov